Literature DB >> 20826898

The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.

Joseph J Grudzinski1, Wolfgang Tomé, Jamey P Weichert, Robert Jeraj.   

Abstract

Biologically effective dose (BED) may be more of a relevant quantity than absorbed dose for establishing tumour response relationships. By taking into account the dose rate and tissue-specific parameters such as repair and radiosensitivity, it is possible to compare the relative biological effects of different targeted radionuclide therapy (TRT) agents. The aim of this work was to develop an analytical tumour BED calculation for TRT that could predict a relative biological effect based on normal body and tumour pharmacokinetics. This work represents a step in the direction of establishing relative pharmacokinetic criteria of when the BED formalism is more applicable than absorbed dose for TRT. A previously established pharmacokinetic (PK) model for TRT was used and adapted into the BED formalism. An analytical equation for the protraction factor, which incorporates dose rate and repair rate, was derived. Dose rates within the normal body and tumour were related to the slopes of their time-activity curves which were determined by the ratios of their respective PK parameters. The relationships between the tumour influx-to-efflux ratio (k(34):k(43)), central compartment efflux-to-influx ratio (k(12):k(21)), central elimination (k(el)), and tumour repair rate (μ), and tumour BED were investigated. As the k(34):k(43) ratio increases and the k(12):k(21) ratio decreases, the difference between tumour BED and D increases. In contrast, as the k(34):k(43) ratios decrease and the k(12):k(21) ratios increase, the tumour BED approaches D. At large k(34):k(43) ratios, the difference between tumour BED and D increases to a maximum as k(el) increases. At small k(34):k(43) ratios, the tumour BED approaches D at very small k(el). At small μ and small k(34):k(43) ratios, the tumour BED approaches D. For large k(34):k(43) ratios, large μ values cause tumour BED to approach D. This work represents a step in the direction of establishing relative PK criteria of when the BED formalism is more applicable than absorbed dose for TRT. It also provides a framework by which the biological effects of different TRT agents can be compared in order to predict efficacy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826898      PMCID: PMC3835526          DOI: 10.1088/0031-9155/55/19/007

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  36 in total

1.  Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy.

Authors:  W T Millar
Journal:  Br J Radiol       Date:  1991-03       Impact factor: 3.039

2.  The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships.

Authors:  D J Brenner; L R Hlatky; P J Hahnfeldt; Y Huang; R K Sachs
Journal:  Radiat Res       Date:  1998-07       Impact factor: 2.841

Review 3.  The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair.

Authors:  R K Sachs; P Hahnfeld; D J Brenner
Journal:  Int J Radiat Biol       Date:  1997-10       Impact factor: 2.694

Review 4.  Dose-rate effects in targeted radiotherapy.

Authors:  R G Dale
Journal:  Phys Med Biol       Date:  1996-10       Impact factor: 3.609

5.  Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants.

Authors:  G R Lazarescu; J J Battista
Journal:  Phys Med Biol       Date:  1997-09       Impact factor: 3.609

6.  Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction?

Authors:  H D Thames; K K Ang; F A Stewart; E van der Schueren
Journal:  Int J Radiat Biol       Date:  1988-07       Impact factor: 2.694

7.  Tumor pretargeting for radioimmunodetection and radioimmunotherapy.

Authors:  H Zhu; R K Jain; L T Baxter
Journal:  J Nucl Med       Date:  1998-01       Impact factor: 10.057

8.  Radiobiological aspects of low dose rates in radioimmunotherapy.

Authors:  J F Fowler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-05       Impact factor: 7.038

9.  Application of the linear-quadratic model to combined modality radiotherapy.

Authors:  Rachel K Bodey; Phil M Evans; Glenn D Flux
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

10.  Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model.

Authors:  P L Roberson; D J Buchsbaum
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

View more
  3 in total

1.  Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Linda M McManus; Beth A Goins
Journal:  Cancer Biother Radiopharm       Date:  2011-08-11       Impact factor: 3.099

Review 2.  Integrated PK-PD and agent-based modeling in oncology.

Authors:  Zhihui Wang; Joseph D Butner; Vittorio Cristini; Thomas S Deisboeck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-01-15       Impact factor: 2.745

3.  Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents.

Authors:  Bryan Bednarz; Joseph Grudzinski; Ian Marsh; Abby Besemer; Dana Baiu; Jamey Weichert; Mario Otto
Journal:  Health Phys       Date:  2018-04       Impact factor: 1.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.